Carvolix SA (EPA:CVX)

France · Delayed Price · Currency is EUR

5.80

-0.06 (-1.02%)

Sep 15, 2026, 5:35 PM CET

Market Cap	347.17M +458.4%
Revenue (ttm)	900.00K -83.2%
Net Income	-24.97M
EPS	n/a
Shares Out	59.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,028
Open	5.88
Previous Close	5.86
Day's Range	5.72 - 5.88
52-Week Range	1.32 - 7.56
Beta	1.09
Analysts	Buy
Price Target	8.78 (+51.38%)
Earnings Date	Sep 25, 2026

About Carvolix

Carvolix SA, a medical technology company, develops and markets minimally invasive minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardiozis technology for treating abdominal aortic aneurysm. The company was formerly known as Affluent Medical SA and changed its name to Carvolix SA in February 20... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2011

Employees 68

Stock Exchange Euronext Paris

Ticker Symbol CVX

Full Company Profile

Financial Performance

In 2025, Carvolix's revenue was 900,000, a decrease of -83.18% compared to the previous year's 5.35 million. Losses were -24.97 million, 69.4% more than in 2024.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for CVX stock is "Buy." The 12-month stock price target is €8.78, which is an increase of 51.38% from the latest price.

Price Target

€8.78

(51.38% upside)

Analyst Consensus: Buy

Stock Forecasts